This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

PALOMA-2 Trial Quality of Life Outcomes

Confidence without Compromise1-2

The PALOMA-2 study shows that you can offer your patients efficacy without compromising QoL with IBRANCE® in combination with letrozole.1

Patient-reported health-related QOL (HRQOL) outcomes was a secondary objective in the PALOMA-2 trial.

A post-hoc analysis of median TTD in FACT-B scores showed a positive trend favouring IBRANCE® + letrozole vs placebo + letrozole (HR: 0.883; P=0.1900).1*

The difference did not reach statistical significance.1

PALOMA-2: Median TTD in FACT-B scores for the PRO-evaluable population in the ITT population4*†§

​​​​​​​Adapted from Rugo HS, et al. Ann Oncol. 2018;29:888-94.1

* In a population of post-menopausal women with ER+/HER2- locally advanced or metastatic breast cancer who had received no prior systemic treatment for their advanced disease.2

FACT-B is a 37-item self-reporting instrument containing the 27-question FACT-G survey and a 10-question breast cancer additional concerns scale. A higher score in any FACT-B assessment indicates better QoL. TTD for FACT-B was defined as the duration between baseline and first occurrence of a decrease of ≥7 points in FACT-B score with no subsequent observation of a <7-point decrease1


§ PRO analyses were based on the PRO-evaluable population (i.e., patients in the intent-to-treat [ITT] population with a baseline and >=1 post-baseline assessment before the end of study treatment) 


ER+ : Oestrogen Receptor-positive, FACT-B : Functional Assessment of Cancer Therapy - Breast, HER2- : Human Epidermal growth factor Receptor 2-negative, HR : Hazard Ratio, QoL : Quality of Life, TTD : Time To Deterioration​​​​​​

 ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References
  1. Rugo HS, et al. Ann Oncol. 2018;29:888-94.
  2. Finn RS, et al. N Engl J Med. 2016;375:1925-1936.
PP-IBR-GBR-3747. July 2021

PALOMA-2 Trial

IBRANCE® + Aromatase Inhibitor (AI) Clinical Trial Results

  • IBRANCE® PALOMA-2 Trial
  • Study Design
  • Efficacy Outcomes
  • Safety Profile
  • IBRANCE® Mode of Action

Efficacy

Efficacy results for IBRANCE®

  • IBRANCE® Efficacy

Safety

IBRANCE® safety information and outcomes

  • IBRANCE® Safety Profile
  • Neutropenia
  • Adverse Event Management

Indication

  • IBRANCE® is indicated for the treatment of HR+ HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No